Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00379977 | Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of Age | PHASE3 | COMPLETED | 30 | — | — | Sep 1, 2006 | Dec 1, 2006 | Oct 12, 2016 | 1 | China |
| Name | Type | Description |
|---|---|---|
| diphtheria, tetanus, pertussis & Hib vaccine | BIOLOGICAL | - |
Inclusion Criteria: * A male or female between, and including, 90 and 120 days of age at the time of the first vaccination Written informed consent obtained from the parent or guardian of the subject Exclusion Criteria: * subjects with known exposure to diphtheria, tetanus, pertussis and/or Haemo...